130 related articles for article (PubMed ID: 29108128)
1. Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system.
Gagne JJ; Houstoun M; Reichman ME; Hampp C; Marshall JH; Toh S
Pharmacoepidemiol Drug Saf; 2018 Jan; 27(1):30-37. PubMed ID: 29108128
[TBL] [Abstract][Full Text] [Related]
2. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial.
Haynes R; Valdes-Marquez E; Hopewell JC; Chen F; Li J; Parish S; Landray MJ; Armitage J; ; ;
Clin Ther; 2019 Sep; 41(9):1767-1777. PubMed ID: 31447131
[TBL] [Abstract][Full Text] [Related]
3. Effects of extended-release niacin with laropiprant in high-risk patients.
; Landray MJ; Haynes R; Hopewell JC; Parish S; Aung T; Tomson J; Wallendszus K; Craig M; Jiang L; Collins R; Armitage J
N Engl J Med; 2014 Jul; 371(3):203-12. PubMed ID: 25014686
[TBL] [Abstract][Full Text] [Related]
4. Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System.
Chrischilles EA; Gagne JJ; Fireman B; Nelson J; Toh S; Shoaibi A; Reichman ME; Wang S; Nguyen M; Zhang R; Izem R; Goulding MR; Southworth MR; Graham DJ; Fuller C; Katcoff H; Woodworth T; Rogers C; Saliga R; Lin ND; McMahill-Walraven CN; Nair VP; Haynes K; Carnahan RM
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):263-271. PubMed ID: 29318683
[TBL] [Abstract][Full Text] [Related]
5. Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs.
Kent S; Haynes R; Hopewell JC; Parish S; Gray A; Landray MJ; Collins R; Armitage J; Mihaylova B;
Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):348-54. PubMed ID: 27407053
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
[TBL] [Abstract][Full Text] [Related]
7. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment.
HPS2-THRIVE Collaborative Group
Eur Heart J; 2013 May; 34(17):1279-91. PubMed ID: 23444397
[TBL] [Abstract][Full Text] [Related]
8. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Chen F; Maccubbin D; Yan L; Sirah W; Chen E; Sisk CM; Davidson M; Blomqvist P; McKenney JM
Int J Cardiol; 2013 Jul; 167(1):225-31. PubMed ID: 22305632
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
Shah S; Ceska R; Gil-Extremera B; Paolini JF; Giezek H; Vandormael K; Mao A; McCrary Sisk C; Maccubbin D
Int J Clin Pract; 2010 May; 64(6):727-38. PubMed ID: 20518948
[TBL] [Abstract][Full Text] [Related]
11. Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database.
Yokoyama S; Tanaka Y; Nakagita K; Hosomi K; Takada M
Int J Med Sci; 2018; 15(14):1686-1693. PubMed ID: 30588192
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the US Food and Drug Administration Sentinel Analysis Tools Using a Comparator with a Different Indication: Comparing the Rates of Gastrointestinal Bleeding in Warfarin and Statin Users.
Carnahan RM; Gagne JJ; Hampp C; Leonard CE; Toh S; Fuller CC; Hennessy S; Hou L; Cocoros NM; Panucci G; Woodworth T; Cosgrove A; Iyer A; Chrischilles EA
Pharmaceut Med; 2019 Feb; 33(1):29-43. PubMed ID: 31933271
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials.
McKenney J; Bays H; Gleim G; Mitchel Y; Kuznetsova O; Sapre A; Sirah W; Maccubbin D
J Clin Lipidol; 2015; 9(3):313-25. PubMed ID: 26073389
[TBL] [Abstract][Full Text] [Related]
14. Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
Dubé MP; Komarow L; Fichtenbaum CJ; Cadden JJ; Overton ET; Hodis HN; Currier JS; Stein JH;
Clin Infect Dis; 2015 Sep; 61(5):840-9. PubMed ID: 25979307
[TBL] [Abstract][Full Text] [Related]
15. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
Morgan JM; Capuzzi DM; Guyton JR
Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
[TBL] [Abstract][Full Text] [Related]
16. Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease: the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/High Triglycerides: Impact on Global Health Outcome (AIM-HIGH) trial.
Teo KK; Goldstein LB; Chaitman BR; Grant S; Weintraub WS; Anderson DC; Sila CA; Cruz-Flores S; Padley RJ; Kostuk WJ; Boden WE;
Stroke; 2013 Oct; 44(10):2688-93. PubMed ID: 23881958
[TBL] [Abstract][Full Text] [Related]
17. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
Capuzzi DM; Guyton JR; Morgan JM; Goldberg AC; Kreisberg RA; Brusco OA; Brody J
Am J Cardiol; 1998 Dec; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666
[TBL] [Abstract][Full Text] [Related]
19. Safety of extended-release niacin/laropiprant in patients with dyslipidemia.
McKenney J; Bays H; Koren M; Ballantyne CM; Paolini JF; Mitchel Y; Betteridge A; Kuznetsova O; Sapre A; Sisk CM; Maccubbin D
J Clin Lipidol; 2010; 4(2):105-112.e1. PubMed ID: 21122637
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
